Jennifer W Mack1, Lie H Chen2, Kimberley Cannavale3, Olivia Sattayapiwat3, Robert M Cooper4, Chun R Chao2. 1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Division of Population Sciences' Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena. 3. Kaiser Permanente Southern California, Pasadena. 4. Department of Pediatric Oncology, Kaiser Permanente Southern California, Pasadena.
Abstract
IMPORTANCE: Cancer is the leading disease-related cause of death among adolescents and young adults (AYAs), but little is known about the care that AYA patients with cancer receive at the end of life (EOL). OBJECTIVE: To evaluate the intensity of EOL care among AYA patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of Kaiser Permanente Southern California (KSPC) cancer registry data and electronic health records for 663 AYA patients with either stage I to III cancer and evidence of cancer recurrence or stage IV cancer at diagnosis. All patients were treated within KSPC, an integrated health care delivery system, and died between 2001 and 2010 before age 40 years (age range at time of death, 15-39 years). MAIN OUTCOMES AND MEASURES: (1) Chemotherapy use in the last 14 days of life; (2) intensive care unit (ICU) care in the last 30 days of life; (3) more than 1 emergency department (ED) visit in the last 30 days of life; (4) hospitalization in the last 30 days of life; and (5) a composite measure of medically intensive EOL care including any of the aforementioned measures. RESULTS: Eleven percent of patients (72 of 663) received chemotherapy within 14 days of death. In the last 30 days of life, 22% of patients (144 of 663) were admitted to the ICU; 22% (147 of 663) had more than 1 ED visit; and 62% (413 of 663) were hospitalized. Overall, 68% of patients (449 of 663) received at least 1 medically intensive EOL care measure. CONCLUSIONS AND RELEVANCE: Most AYA patients received at least 1 form of medically intensive EOL care. These findings suggest the need to better understand EOL care preferences and decision making in this young population.
IMPORTANCE: Cancer is the leading disease-related cause of death among adolescents and young adults (AYAs), but little is known about the care that AYA patients with cancer receive at the end of life (EOL). OBJECTIVE: To evaluate the intensity of EOL care among AYA patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of Kaiser Permanente Southern California (KSPC) cancer registry data and electronic health records for 663 AYA patients with either stage I to III cancer and evidence of cancer recurrence or stage IV cancer at diagnosis. All patients were treated within KSPC, an integrated health care delivery system, and died between 2001 and 2010 before age 40 years (age range at time of death, 15-39 years). MAIN OUTCOMES AND MEASURES: (1) Chemotherapy use in the last 14 days of life; (2) intensive care unit (ICU) care in the last 30 days of life; (3) more than 1 emergency department (ED) visit in the last 30 days of life; (4) hospitalization in the last 30 days of life; and (5) a composite measure of medically intensive EOL care including any of the aforementioned measures. RESULTS: Eleven percent of patients (72 of 663) received chemotherapy within 14 days of death. In the last 30 days of life, 22% of patients (144 of 663) were admitted to the ICU; 22% (147 of 663) had more than 1 ED visit; and 62% (413 of 663) were hospitalized. Overall, 68% of patients (449 of 663) received at least 1 medically intensive EOL care measure. CONCLUSIONS AND RELEVANCE: Most AYA patients received at least 1 form of medically intensive EOL care. These findings suggest the need to better understand EOL care preferences and decision making in this young population.
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Pang-Hsiang Liu; Mary Beth Landrum; Jane C Weeks; Haiden A Huskamp; Katherine L Kahn; Yulei He; Jennifer W Mack; Nancy L Keating Journal: J Palliat Med Date: 2014-04-17 Impact factor: 2.947
Authors: Craig C Earle; Ann B Nattinger; Arnold L Potosky; Kathleen Lang; Rajiv Mallick; Mark Berger; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Kelly M Trevino; Caroline H Abbott; Michael J Fisch; Robert J Friedlander; Paul R Duberstein; Holly G Prigerson Journal: Cancer Date: 2014-05-28 Impact factor: 6.860
Authors: June Dong Park; Hyoung Jin Kang; Young Ae Kim; MinKyoung Jo; Eun Sook Lee; Hee Young Shin; Young Ho Yun Journal: PLoS One Date: 2014-06-12 Impact factor: 3.240
Authors: Douglas L Hill; Jennifer K Walter; Jessica A Casas; Concetta DiDomenico; Julia E Szymczak; Chris Feudtner Journal: Support Care Cancer Date: 2018-04-07 Impact factor: 3.603
Authors: Douglas L Hill; Jennifer K Walter; Julia E Szymczak; Concetta DiDomenico; Shefali Parikh; Chris Feudtner Journal: J Pain Symptom Manage Date: 2019-08-16 Impact factor: 3.612
Authors: Shrujal S Baxi; Minal Kale; Salomeh Keyhani; Benjamin R Roman; Annie Yang; Antonio P Derosa; Deborah Korenstein Journal: Med Care Date: 2017-07 Impact factor: 2.983
Authors: Jennifer W Mack; Kimberly Cannavale; Olivia Sattayapiwat; Bianca Cheung; Lie H Chen; Robert M Cooper; Chun R Chao Journal: J Palliat Med Date: 2016-08-02 Impact factor: 2.947
Authors: J M Snaman; A C Talleur; J Lu; D R Levine; E C Kaye; A Sykes; Z Lu; B M Triplett; J N Baker Journal: Bone Marrow Transplant Date: 2017-11-13 Impact factor: 5.483